Table 3.
Toxicities to DA-R-EPOCH regimen in this study as compared to the prospective study by Duleavy et al. (6)
Toxicities (Grade 3/4) | Dunleavy et al6 (n = 51) | Present Study (n = 37) |
---|---|---|
Hospitalization for FN | 13% of cycles |
23% of cycles (23/219) 14 (37.8%) patients |
Anemia | Not reported | 9 (24.3%) |
Peripheral Neuropathy | 8 (15.7%) | 7 (18.9%) |
Mucositis | 4 (7.8%) | 4 (10.8%) |
Ileus | 0 | 1 (2.7%) |
Left ventricular dysfunction | 0 | 1 (2.7%) |
AML | 1 (1.9%) | 0 |